Innovacell Inc. is a biotechnology company based in Tokyo, Japan, focused on developing and manufacturing regenerative medicine products for treating fecal and urinary incontinence. The company specializes in cell therapy solutions aimed at addressing significant unmet medical needs in these areas. Its notable products include ICEF15, a cell therapy for urgent fecal incontinence; ICEF16 for leaky fecal incontinence; and ICES13 for stress urinary incontinence. Innovacell went public on the Tokyo Stock Exchange Growth Market on February 24, 2026, under the ticker symbol 504A, offering approximately 9.13 million shares at an indicative price range of 1,290 to 1,350 yen per share, aiming to raise about 12.32 billion yen. As of July 2026, the company employed 48 people. Recent developments include a 1 billion yen investment from Alfresa Corporation and successful completion of a Series D funding round, raising over 7.3 billion yen.
AI-researched from public web sources — may contain errors or omissions and is not a substitute for verifying independently.
Innovacell Inc.'s offering is currently listed on JPX. The expected date is Feb 24, 2026. Shares are expected to be offered at ¥1,350 (~$9.00 USD), with 8.4M shares on offer. The proposed ticker is 504A. Innovacell Inc. is headquartered in Japan. It is classified under Biotech.
The dates below are calculated from widely-used industry conventions, not from this offering's own disclosed terms — DiscoverIPO does not have a structured source for the actual figures. Treat them as reference points, not confirmed dates.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Innovacell Inc..
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/innovacell" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Innovacell Inc. — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/innovacell?theme=light as the src instead.
https://www.discoveripo.com/ipo/innovacell/opengraph-image
Innovacell Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/innovacell?utm_source=embed&utm_medium=text&utm_campaign=innovacell
Get emailed when Innovacell Inc.'s terms, price, or expected date change — no weekly noise, just this company.
Innovacell Inc. is expected to list on Feb 24, 2026.
Innovacell Inc. is listing on JPX.
Innovacell Inc.'s proposed ticker is 504A.
Innovacell Inc. is a biotechnology company based in Tokyo, Japan, focused on developing and manufacturing regenerative medicine products for treating fecal and urinary incontinence. The company specializes in cell therapy solutions aimed at addressing significant unmet medical needs in these areas. Its notable products include ICEF15, a cell therapy for urgent fecal incontinence; ICEF16 for leaky fecal incontinence; and ICES13 for stress urinary incontinence. Innovacell went public on the Tokyo Stock Exchange Growth Market on February 24, 2026, under the ticker symbol 504A, offering approximately 9.13 million shares at an indicative price range of 1,290 to 1,350 yen per share, aiming to raise about 12.32 billion yen. As of July 2026, the company employed 48 people. Recent developments include a 1 billion yen investment from Alfresa Corporation and successful completion of a Series D funding round, raising over 7.3 billion yen.
Japan Exchange Group new-listings page. Retrieved Aug 3, 2026.
View the original filing on JPX →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy